{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:37:39Z","timestamp":1794940659871,"version":"4.9.1"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology"],"published-print":{"date-parts":[[2011,1,18]]},"DOI":"10.1212\/wnl.0b013e318207b1f6","type":"journal-article","created":{"date-parts":[[2011,1,17]],"date-time":"2011-01-17T21:37:05Z","timestamp":1295300225000},"page":"294-300","source":"Crossref","is-referenced-by-count":312,"title":["Evidence-based guideline update: Plasmapheresis in neurologic disorders [RETIRED]"],"prefix":"10.1212","volume":"76","member":"276","container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.0b013e318207b1f6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T10:22:05Z","timestamp":1732443725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.0b013e318207b1f6"}},"subtitle":["Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology"],"short-title":[],"issued":{"date-parts":[[2011,1,18]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,1,18]]}},"alternative-id":["10.1212\/WNL.0b013e318207b1f6"],"URL":"https:\/\/doi.org\/10.1212\/wnl.0b013e318207b1f6","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,18]]}}}